---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-023169"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:28:40.174370+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cellectar Biosciences reports FY2025 net loss $21.8M, cash $13.2M; plans EMA submission Q3 2026

## Summary
- Net loss $21.8M ($8.35/share) vs $44.6M ($36.52/share) in 2024; company pre-revenue.
- Cash $13.2M at Dec 31, 2025, expected to fund operations into Q3 2026.
- Plans to submit Conditional Marketing Authorization for iopofosine I 131 to EMA in Q3 2026.
- Initiated Phase 1b study of CLR 125 in triple negative breast cancer; early data mid-2026.
- Received FDA Breakthrough Therapy Designation for iopofosine I 131 in relapsed/refractory WM.

## SEC filing metadata
- accession: 0001104659-26-023169
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465926023169/0001104659-26-023169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465926023169/tm267955d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-023169
- JSON: https://secwatch.observer/filing/0001104659-26-023169.json
- Plain text: https://secwatch.observer/filing/0001104659-26-023169.txt

## Key facts
- Earnings Releases
  Cellectar Biosciences, Inc. reported the year ended December 31, 2025 results: net income $21.8 million, EPS $8.35 per basic and diluted share.
  - Period: the year ended December 31, 2025
  - Net income: $21.8 million
  - EPS: $8.35 per basic and diluted share
  - Result: reported results
  source text: Net loss for the full year ending December 31, 2025, was $21.8 million or $8.35 per basic and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465926023169/0001104659-26-023169-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.